Geri
MetaStat Inc (MTST) Fiyatı
MTST Hisse Senedi Fiyat Grafiği
MTST Kazanmak
MetaStat Inc
$0
0%
$0
Kapanışta: Feb 06, 16:00:00 GMT-5
$0
0%
$0
Sonrası Piyasa: Feb 06, 20:00:00 GMT-5
Henüz Veri YokEarnings FAQ
MTST'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
MetaStat Inc MTST'ün son çeyrekteki geliri nasıl performans gösterdi?
MetaStat Inc'in gelir tahmini nedir?
MetaStat Inc'in kazanç kalite puanı nedir?
MetaStat Inc kazançlarını ne zaman rapor eder?
MetaStat Inc'in beklenen kazançları nelerdir?
MetaStat Inc kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$0.0006
Açılış fiyatı
$0.0001
Günün Aralığı
$0.0001 - $0.0006
52 haftalık aralık
$0.0001 - $0.0007
İşlem hacmi
16.9K
Ort.Hacim
181
EPS (TTM)
-0.57
Dividend yield
--
Piyasa Değeri
$3.5K
MTST nedir?
MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Boston, Massachusetts. The company went IPO on 2008-02-13. The firm's therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The firm's product development programs are focused on developing drug candidates and companion diagnostic tests that target the MENA pathway. Its pipelines include MENA Diagnostic Assay and MetaSite Breast Assay. The MENA diagnostic assay is a tissue-based quantitative immunofluorescence (QIF) test that measures expression of the pro-metastatic MENA protein splice-variant which is associated with poor outcomes and metastasis in early-stage breast cancer (ESBC) and squamous cell carcinoma of the Lung. MetaSite Breast is an immunohistochemistry test (IHC) that measures micro-anatomical intravasation sites (TMEM) at blood vessels within the tumor microenvironment which are clinically validated as prognostic markers of metastasis in hormone receptor-positive (HR+) ESBC.
Özellikler
Ticaret Stratejileri
Kaynaklar
© 2025 Finture Development Limited. All rights reserved